Loading...
XJPX
2160
Market cap888mUSD
Jul 10, Last price  
2,605.00JPY
1D
0.66%
1Q
-18.08%
Jan 2017
258.49%
IPO
864.81%
Name

GNI Group Ltd

Chart & Performance

D1W1MN
XJPX:2160 chart
P/E
—
P/S
5.41
EPS
—
Div Yield, %
—
Shrs. gr., 5y
3.18%
Rev. gr., 5y
22.39%
Revenues
26.84b
+13.67%
273,588,000204,346,000204,346,000109,115,727272,876,00090,332,000161,943,000183,600,000474,717,0001,016,670,0001,306,931,0002,648,451,0005,018,944,0007,446,067,0009,773,862,00012,690,246,00017,418,966,00026,010,571,00023,611,705,00026,840,000,000
Net income
-4.41b
L
-1,279,454,000-1,366,385,000-1,366,385,000-618,405,533-258,088,000-435,450,000-482,255,000-730,776,000-317,274,000-623,150,000-513,100,000-175,206,000-200,132,000181,841,0001,258,127,0001,066,185,000388,826,0008,094,203,0001,098,234,000-4,412,000,000
CFO
-2.41b
L-23.90%
-1,031,582,000-942,814,000-942,814,000-216,583,000-130,543,000-163,989,000-351,819,000-662,821,000-567,075,000-382,203,000-518,714,000-476,605,000621,230,000788,587,0001,377,519,000552,268,000393,320,0006,549,337,000-3,164,422,000-2,408,000,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

GNI Group Ltd. is a global biopharmaceutical enterprise dedicated to the research, development, manufacturing, and commercialization of both modern pharmaceuticals and traditional Chinese medicines. The company's lead product, Etuary, is currently available for the treatment of idiopathic pulmonary fibrosis. Beyond this, Etuary is undergoing further clinical evaluation: it is in Phase III trials for connective tissue disease-associated interstitial lung disease, and in Phase II along with a pre-Phase III pilot study for radiation pneumonitis. Investigations are also underway for its application in diabetic nephropathy. GNI Group Ltd.'s pipeline additionally features F351, which is in Phase II development for liver fibrosis; F573, an early-stage compound in pre-clinical testing for acute-on-chronic liver failure; and Tamibarotene, intended for the treatment of acute promyelocytic leukemia. Established in 2001, the company's headquarters are located in Tokyo, Japan.
URL
https://www.gnipharma.com/
IPO date
Aug 31, 2007
Employees
701
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT